Metastatic Castration-Resistant Prostate Cancer Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working, DelveInsight | Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceutica

Metastatic Castration-Resistant Prostate Cancer emerging therapies such as JEVTANA (Cabazitaxel), XOFIGO (radium-223), Opevesostat (MK-5684; ODM-208), TRUQAP (capivasertib, AZD 5363), and others are expected to boost the Metastatic Castration-Resistant Prostate Cancer Market in the upcoming years.

DelveInsight has launched a new report on "Metastatic Castration-Resistant Prostate Cancer - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Metastatic Castration-Resistant Prostate Cancer, historical and forecasted epidemiology as well as the Metastatic Castration-Resistant Prostate Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Download our free report on metastatic castration-resistant prostate cancer @ https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Metastatic Castration-Resistant Prostate Cancer Market Report:

In 2023, the total metastatic castration-resistant prostate cancer (mCRPC) market size across the seven major markets (7MM) was estimated at approximately USD 6.8 billion. This market is expected to grow positively by 2034, driven by the rising prevalence of prostate cancer in emerging markets, influenced by lifestyle changes, aging populations, and improved healthcare access.
In September 2024, Ipsen announced that the Phase III CONTACT-02 trial evaluating Cabometyx® and atezolizumab in mCRPC demonstrated a non-significant improvement in overall survival but successfully met the progression-free survival (PFS) endpoint.
In September 2024, Foundation Medicine received FDA approval for FoundationOne®CDx and Liquid CDx as companion diagnostics for Lynparza® in BRCA-mutated mCRPC.
In July 2024, results from the ARANOTE trial indicated that NUBEQA® plus ADT significantly improved radiological PFS in metastatic hormone-sensitive castrate-resistant prostate cancer (mHSPC).
In July 2024, the FDA granted fast-track designation to SYNC-T SV-102 for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
In June 2024, Kangpu Biopharmaceuticals received FDA approval to initiate a Phase II/III trial evaluating KPG-121 in combination with Abiraterone for mCRPC.
The United States held the largest market share, contributing around 64% of the total mCRPC therapeutic market in the 7MM.
Recent FDA approvals in 2023 introduced AKEEGA (niraparib + abiraterone acetate) and TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) for mCRPC treatment. Other approved therapies over the past few years include XTANDI, PROVENGE, JEVTANA, ZYTIGA, LYNPARZA, and others. The mCRPC market also saw the approval of PLUVICTO (Novartis' radioligand therapy) in 2022, which generated unexpected revenue in the third-line mCRPC setting.
Among androgen deprivation therapies (ADTs), XTANDI and abiraterone acetate remain the dominant treatments, heavily prescribed in first- and second-line mCRPC treatment. In 2023, XTANDI accounted for the largest market share in mCRPC, approximately 41% across the 7MM.
Several biopharmaceutical companies are actively investigating potential therapies for mCRPC across various treatment lines. Key players include Curium, Bristol-Myers Squibb, Merck & Orion, Pfizer, Merus, Zenith Epigenetics, MacroGenics, Laekna Therapeutics, Ipsen, AstraZeneca, Telix International, ESSA Pharma, Arvinas & Novartis, Lantheus, Eli Lilly/POINT Biopharma, Xencor, and Promontory Therapeutics.
The mCRPC pipeline appears strong, with notable first-line candidates including Merck's Opevesostat, ESSA Pharma's Masofaniten, and Tavanta's TAVT-45.
In the second-line setting, CABOMETYX is expected to be among the first emerging therapies to receive approval.
For third-line and beyond, potential candidates include Lantheus and Eli Lilly/POINT Biopharma's radioligand 177Lu-PNT2002, AstraZeneca's actinium-225-based PSMA-targeting radio-conjugate FPI-2265, and Arvinas/Novartis' PROTAC AR degrader, ARV-766.
In 2023, the seven major markets (7MM) recorded approximately 7.28 million prevalent cases of prostate cancer. This number is projected to increase over the 2024-2034 forecast period, driven by an aging population and advancements in diagnostic technologies.
In the United States, the five-year prevalence of prostate cancer was estimated at around 1.09 million cases in 2023.
Among the EU4 and the UK, Germany had the highest number of metastatic castration-resistant prostate cancer (mCRPC) cases, while Spain reported the lowest cases in 2023.
Overall, the mCRPC market is poised for significant growth throughout the forecast period. The expansion of approved therapies through label extensions and the introduction of innovative emerging treatments will be key factors driving market expansion.
Key Metastatic Castration-Resistant Prostate Cancer companies such as Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others are evaluating new drugs for Metastatic Castration-Resistant Prostate Cancer to improve the treatment landscape.
Promising Metastatic Castration-Resistant Prostate Cancer pipeline therapies in various stages of development include JEVTANA (Cabazitaxel), XOFIGO (radium-223), Opevesostat (MK-5684; ODM-208), TRUQAP (capivasertib, AZD 5363), and others.
To know more interesting facts about metastatic castration-resistant prostate cancer market @ https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Metastatic Castration-Resistant Prostate Cancer market report:
Metastatic Castration-Resistant Prostate Cancer market report covers a descriptive overview and comprehensive insight of the Metastatic Castration-Resistant Prostate Cancer Epidemiology and Metastatic Castration-Resistant Prostate Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Metastatic Castration-Resistant Prostate Cancer market report provides insights on the current and emerging therapies.
Metastatic Castration-Resistant Prostate Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Metastatic Castration-Resistant Prostate Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Metastatic Castration-Resistant Prostate Cancer market.

Got queries? Click here to know more about the Metastatic Castration-Resistant Prostate Cancer Market Landscape https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Metastatic Castration-Resistant Prostate Cancer Overview
Prostate cancer is a malignancy that develops in the prostate gland. It typically progresses slowly and remains confined to the prostate in its early stages, often causing no significant harm. While it is most common in men aged 50-64 and those over 65, it can also occur in younger individuals under 50.
Symptoms of prostate adenocarcinoma may include blood in the semen, frequent urination, and pain during urination. In many cases, symptoms do not appear until the prostate enlarges enough to obstruct the urethra, the tube that carries urine from the bladder.
Diagnosing prostate cancer involves a combination of tests, including:
PSA blood test to measure prostate-specific antigen levels
Digital rectal exam (DRE) to detect abnormalities in the prostate
Biopsy to analyze tissue samples for cancerous cells
Genetic testing to identify hereditary risk factors
Imaging tests such as ultrasound or MRI to visualize the prostate
Bone scans (if needed) to check for cancer spread
These diagnostic methods are often used together to provide a comprehensive assessment of prostate health and detect early signs of cancer.
Metastatic Castration-Resistant Prostate Cancer Market Outlook
The current standard therapy for castration-resistant prostate cancer (CRPC), in addition to androgen deprivation therapy (ADT), includes:
Sipuleucel-T
Chemotherapy (docetaxel for patients without prior use; cabazitaxel for those previously treated with docetaxel)
Abiraterone acetate and enzalutamide
PARP inhibitors such as olaparib and rucaparib (for patients with DNA damage repair gene mutations)
Radium-223 (for patients with bone metastases)
Despite these treatment options, mCRPC remains a lethal disease, and more effective therapeutic strategies are essential to improve clinical outcomes.
Until 2010, docetaxel was the only available treatment for mCRPC, demonstrating a survival benefit over previous standard therapies. It was FDA-approved in 2004 for mCRPC in combination with prednisone. For years, patients who progressed after first-line docetaxel had no standard treatment options. However, in recent years, several new therapies have received regulatory approval in the United States, including PROVENGE, JEVTANA, ZYTIGA, XTANDI, LYNPARZA, TALZENNA, AKEEGA, and others.
The successful development of PARP inhibitors has significantly expanded the treatment landscape for mCRPC patients with DNA damage repair gene mutations, enabling more personalized treatment approaches. PARP inhibitors have made remarkable progress, with:
AKEEGA (Janssen)
TALZENNA (Pfizer/Astellas Pharma)
LYNPARZA (AstraZeneca/Merck) in combination
These therapies were all approved for mCRPC in 2023.
Additionally, in 2022, Novartis' PLUVICTO, a PSMA-targeted radioligand therapy, received FDA approval for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), further enhancing treatment options for advanced-stage patients.
Request for a metastatic castration-resistant prostate cancer market sample page @ https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Metastatic Castration-Resistant Prostate Cancer Marketed mCRPC Drugs:
JEVTANA (Cabazitaxel): Sanofi
XOFIGO (radium-223): Bayer

Metastatic Castration-Resistant Prostate Cancer Emerging mCRPC Drugs:
Opevesostat (MK-5684; ODM-208): Merck and Orion
TRUQAP (capivasertib, AZD 5363): AstraZeneca
Scope of the Metastatic Castration-Resistant Prostate Cancer Market Report

Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Metastatic Castration-Resistant Prostate Cancer Companies: Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others
Key Metastatic Castration-Resistant Prostate Cancer Therapies: JEVTANA (Cabazitaxel), XOFIGO (radium-223), Opevesostat (MK-5684; ODM-208), TRUQAP (capivasertib, AZD 5363), and others
Metastatic Castration-Resistant Prostate Cancer Therapeutic Assessment: Metastatic Castration-Resistant Prostate Cancer current marketed and Metastatic Castration-Resistant Prostate Cancer emerging therapies
Metastatic Castration-Resistant Prostate Cancer Market Dynamics: Metastatic Castration-Resistant Prostate Cancer market drivers and Metastatic Castration-Resistant Prostate Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Metastatic Castration-Resistant Prostate Cancer Unmet Needs, KOL's views, Analyst's views, Metastatic Castration-Resistant Prostate Cancer Market Access and Reimbursement
Read more about the scope of our metastatic castration-resistant prostate cancer market report @ https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Metastatic Castration-Resistant Prostate Cancer Patient Share (%) Overview at a Glance
5. Metastatic Castration-Resistant Prostate Cancer Market Overview at a Glance
6. Metastatic Castration-Resistant Prostate Cancer Disease Background and Overview
7. Metastatic Castration-Resistant Prostate Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Metastatic Castration-Resistant Prostate Cancer
9. Metastatic Castration-Resistant Prostate Cancer Current Treatment and Medical Practices
10. Unmet Needs
11. Metastatic Castration-Resistant Prostate Cancer Emerging Therapies
12. Metastatic Castration-Resistant Prostate Cancer Market Outlook
13. Country-Wise Metastatic Castration-Resistant Prostate Cancer Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Metastatic Castration-Resistant Prostate Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Metastatic Castration-Resistant Prostate Cancer Market Outlook 2034 https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Metastatic Castration-Resistant Prostate Cancer Pipeline Insights, DelveInsight

"Metastatic Castration-Resistant Prostate Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Metastatic Castration-Resistant Prostate Cancer market. A detailed picture of the Metastatic Castration-Resistant Prostate Cancer pipeline landscape is provided, which includes the disease overview and Metastatic Castration-Resistant Prostate Cancer treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.